摘要
目的为我国药品价格专家评审工作提供参考。方法对德国创新药物定价决策中专家咨询制度进行描述和分析,联系我国药品价格专家评审制度,分析二者的相似点和差异,明确德国经验对我国药品价格专家评审工作的借鉴意义。结果两个专家体系在专家遴选等方面有很多相似之处,但在专家的组织形式、专家库设置目的及专家在药品价格决策中的作用的诸多方面存在很大差异。结论我国应当借鉴德国经验,分散专家资源,展开动态价格评审;调整专家角色,规范专家在药品价格决策中的作用。在不断探索和实践中促进药品价格决策的科学化进程。
Objective To provide a reference for the work of expert evaluation in drug pricing. Methods Expert advisory system in innovative drug pricing decision-making in Germany was introduced. Expert mechanisms in Germany innovative drug pricing decision-making and Chinese drug pricing evaluation were compared. The similarities and differences between the two were analyzed. The reference meaning of expert advisory system in Germany innovative drug pricing was defined. Results There are many similarities between the two expert systems in the selection of experts and other aspects,but differences existed in expert organization,the purpose of expert database setting-up and many aspects of and role of experts in drug pricing decision-making. Conclusions German expert advisory system in innovative drug pricing decision-making is worth learning. China should develop dynamic price reviewand adjust the role of experts in drug pricing decision-making. Expert mechanism in scientific drug decision-making should be accelerated in continual exploration and practice.
出处
《沈阳药科大学学报》
CAS
CSCD
北大核心
2015年第6期492-495,502,共5页
Journal of Shenyang Pharmaceutical University
关键词
外部专家
专家咨询
专家评审
药品定价决策
external expert
expert advisory
expert review
drug pricing decision-making
